UY31130A1 - Nuevos compuestos ligandos del receptor de la adenosina a3 - Google Patents
Nuevos compuestos ligandos del receptor de la adenosina a3Info
- Publication number
- UY31130A1 UY31130A1 UY31130A UY31130A UY31130A1 UY 31130 A1 UY31130 A1 UY 31130A1 UY 31130 A UY31130 A UY 31130A UY 31130 A UY31130 A UY 31130A UY 31130 A1 UY31130 A1 UY 31130A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- general formula
- adenosine
- solvates
- isomers
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 102000008161 Adenosine A3 Receptor Human genes 0.000 abstract 1
- 108010060261 Adenosine A3 Receptor Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
Abstract
La presente invención se refiere a los ligandos del receptor de adenosina A3 de fórmula general (I), dentro de ellos los favorables a los antagonistas, a sus sales, solvatos, N-óxidos e isómeros, a las composiciones farmacéuticas que contienen los compuestos de fórmula general (I), sus sales, solvatos, N-óxidos e isómeros, al uso de los compuestos de fórmula general (I), sus sales, solvatos, N-óxidos e isómeros, a la preparación de compuestos de fórmula general (I), sus sales, solvatos, N-óxidos e isómeros, así como a los nuevos intermediarios de fórmula general (II), (VI), (XI), (XII) y (XV) y a la preparación de ellos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0700395A HUP0700395A2 (en) | 2007-06-07 | 2007-06-07 | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31130A1 true UY31130A1 (es) | 2009-01-30 |
Family
ID=89987565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY31130A UY31130A1 (es) | 2007-06-07 | 2008-06-06 | Nuevos compuestos ligandos del receptor de la adenosina a3 |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG176983A1 (en) | 2009-07-08 | 2012-02-28 | Dermira Canada Inc | Tofa analogs useful in treating dermatological disorders or conditions |
| FR3053968A1 (fr) * | 2016-07-13 | 2018-01-19 | Biomerieux | Reactifs pour la protection reversible de molecules biologiques |
| MA45202B1 (fr) * | 2016-09-24 | 2022-04-29 | Kbp Biosciences Co Ltd | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation |
| MA52422A (fr) | 2018-02-27 | 2021-01-06 | Incyte Corp | Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| MA53097A (fr) | 2018-07-05 | 2021-05-12 | Incyte Corp | Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b |
| CR20210271A (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso |
| MA54551A (fr) | 2018-12-20 | 2021-10-27 | Incyte Corp | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
| GR76063B (es) * | 1981-04-03 | 1984-08-03 | Roussel Uclaf | |
| ZA836701B (en) * | 1982-10-01 | 1984-10-31 | Roussel Uclaf | Imidazo(1,2-a)quinolines |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| EA006854B1 (ru) * | 2001-05-31 | 2006-04-28 | Санофи-Авентис | Производные аминохинолина и его применение в качестве лигандов аденозина a |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| WO2003053973A1 (de) | 2001-12-21 | 2003-07-03 | Jsw-Research Forschungslabor Gmbh | Pyrazolyl-substituierte triazolochinoxaline |
| HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| MEP19108A (en) * | 2003-07-31 | 2010-06-10 | Sanofi Aventis | Aminoquinoline derivatives and their use as adenosine a3 ligands |
-
2007
- 2007-06-07 HU HU0700395A patent/HUP0700395A2/hu unknown
-
2008
- 2008-02-06 UA UAA200913976A patent/UA99463C2/ru unknown
- 2008-06-02 AU AU2008259534A patent/AU2008259534B2/en not_active Ceased
- 2008-06-02 WO PCT/HU2008/000063 patent/WO2008149168A1/en not_active Ceased
- 2008-06-02 BR BRPI0812257-1A2A patent/BRPI0812257A2/pt not_active IP Right Cessation
- 2008-06-02 KR KR1020107000342A patent/KR20100031610A/ko not_active Ceased
- 2008-06-02 CA CA002689612A patent/CA2689612A1/en not_active Abandoned
- 2008-06-02 MX MX2009013209A patent/MX2009013209A/es active IP Right Grant
- 2008-06-02 ME MEP-2009-340A patent/ME00958B/me unknown
- 2008-06-02 AT AT08762666T patent/ATE502016T1/de active
- 2008-06-02 DK DK08762666.9T patent/DK2167470T3/da active
- 2008-06-02 DE DE602008005589T patent/DE602008005589D1/de active Active
- 2008-06-02 ES ES08762666T patent/ES2363672T3/es active Active
- 2008-06-02 NZ NZ581186A patent/NZ581186A/en not_active IP Right Cessation
- 2008-06-02 SI SI200830255T patent/SI2167470T1/sl unknown
- 2008-06-02 EP EP08762666A patent/EP2167470B1/en active Active
- 2008-06-02 HR HR20110332T patent/HRP20110332T1/hr unknown
- 2008-06-02 CN CN2008800191923A patent/CN101679272B/zh not_active Expired - Fee Related
- 2008-06-02 JP JP2010510891A patent/JP5487100B2/ja not_active Expired - Fee Related
- 2008-06-02 PT PT08762666T patent/PT2167470E/pt unknown
- 2008-06-02 MY MYPI20095180A patent/MY148654A/en unknown
- 2008-06-02 RU RU2009149518/04A patent/RU2489432C2/ru not_active IP Right Cessation
- 2008-06-02 PL PL08762666T patent/PL2167470T3/pl unknown
- 2008-06-05 CL CL200801648A patent/CL2008001648A1/es unknown
- 2008-06-05 PE PE2008000960A patent/PE20090325A1/es not_active Application Discontinuation
- 2008-06-05 JO JO2008263A patent/JO2689B1/en active
- 2008-06-05 AR ARP080102391A patent/AR066873A1/es not_active Application Discontinuation
- 2008-06-05 PA PA20088782901A patent/PA8782901A1/es unknown
- 2008-06-06 UY UY31130A patent/UY31130A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121025A patent/TWI424998B/zh not_active IP Right Cessation
-
2009
- 2009-11-13 TN TNP2009000482A patent/TN2009000482A1/fr unknown
- 2009-11-20 GT GT200900301A patent/GT200900301A/es unknown
- 2009-11-23 ZA ZA2009/08280A patent/ZA200908280B/en unknown
- 2009-11-24 SV SV2009003420A patent/SV2009003420A/es unknown
- 2009-12-02 IL IL202471A patent/IL202471A0/en unknown
- 2009-12-03 NI NI200900210A patent/NI200900210A/es unknown
- 2009-12-04 DO DO2009000276A patent/DOP2009000276A/es unknown
- 2009-12-04 EC EC2009009783A patent/ECSP099783A/es unknown
- 2009-12-04 US US12/631,139 patent/US8338411B2/en not_active Expired - Fee Related
- 2009-12-04 HN HN2009003357A patent/HN2009003357A/es unknown
- 2009-12-16 CR CR11171A patent/CR11171A/es unknown
-
2010
- 2010-01-06 CO CO10001036A patent/CO6270233A2/es active IP Right Grant
- 2010-01-07 MA MA32498A patent/MA31738B1/fr unknown
-
2011
- 2011-05-30 CY CY20111100519T patent/CY1111644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099783A (es) | Nuevos compuestos ligandos del receptor de la adenosina a3 | |
| DOP2009000039A (es) | COMPUESTOS DE PIRIDO (2,3-D) PIRIMIDINONA Y SU USO COMO INHIBIDORES DE P13-Ka | |
| ECSP088265A (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| DOP2010000047A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
| UY31166A1 (es) | Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica | |
| UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
| CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| CO6531479A2 (es) | Derivados de espirolactama y uso de los mismos | |
| CR11828A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico | |
| EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
| UY28765A1 (es) | Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico | |
| ECSP10010200A (es) | Derivados de pirazol como inhibidores de 5-lo | |
| UY31338A1 (es) | Compuestos novedosos activos como antagonistas de receptores muscarinicos | |
| CR9595A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
| ECSP077979A (es) | Potenciadores del receptor ampa | |
| CU23564A3 (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| CU20110003A7 (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20171006 |